Limb Lengthening Expert Dr. Dror Paley Opens First Clinic in Middle East at UAE’s Burjeel Medical City
As part of its ongoing efforts to focus on complex care and pediatric sub-specialties, Burjeel Holdings, one of the leading private healthcare services providers in the MENA region, in collaboration with renowned orthopedic surgeon Dr. Dror Paley, has launched a clinic in the UAE. The Paley Middle East Clinic, located at Burjeel Medical City (BMC) in Abu Dhabi, aims to become a hub for complex procedures in the region by providing world-class specialized orthopedic care. It is the first clinic in the Middle East and Asia by Dr. Paley, who has performed around 20,000 limb-lengthening and reconstruction-related procedures.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230110005563/en/
Dr. Dror Paley and his team at Paley Middle East Clinic in Burjeel Medical City with Dr. Shamsheer-Vayalil, Founder and Chairman, Burjeel Holdings, and other senior management officials. (Photo: AETOSWire)
Dr. Paley is internationally recognized for his expertise in limb lengthening, deformity reconstruction, and joint preservation of children and adults. The clinic at BMC offers diagnosis and treatment of special orthopedic conditions, including congenital limb deformities, post-traumatic limb conditions, bone healing problems, bone defects, skeletal dysplasia, metabolic disorders, foot deformities, and peripheral nerve disorders.
BMC, one of the leading quaternary care facilities in the UAE, expects the clinic, supported by a comprehensive rehabilitation department, to serve as a beacon for orthopedic surgical excellence and innovation.
“I am delighted to start my innings in the UAE with BMC. Together we aim to transform the UAE into a hub for limb lengthening and deformity correction, attracting patients from across the globe for cutting-edge treatments,” said Dr. Paley.
Welcoming Dr. Paley, Mr. John Sunil, CEO, Burjeel Holdings, said, “The collaboration is yet another important step in the Group’s pursuit of delivering healthcare excellence and improving patient outcomes. We are constantly investing in and establishing new partnerships to identify cutting-edge medical technologies and innovations that can help us deliver complex care to the people. Dr. Paley’s expertise will help the people avail of almost every aspect of orthopedic and neurosurgical care, making the UAE a sought-after hub for such services.”
About Burjeel Medical City
Burjeel Medical City is a 400-bed multi-specialty hospital and quaternary care center located in Abu Dhabi, UAE. It offers high-quality specialized treatment and complex care in over 40 adult and pediatric specialties, aided by state-of-the-art medical technology and an international team of experts.
Find more information at https://www.burjeelmedicalcity.com/
*Source: AETOSWire
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230110005563/en/
Contact information
M. Unnikrishnan
krish@burjeelholdings.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Decent Cybersecurity to Showcase Post-Quantum Solutions at DSEI Japan 202516.5.2025 10:49:00 EEST | Press release
Decent Cybersecurity announces its participation at DSEI Japan 2025 as the only Slovak cybersecurity company exhibiting at this premier defense event in Makuhari Messe, Chiba (May 21-23, 2025). The company will showcase its advanced post-quantum security solutions for aerospace, defense, and space sectors, including SpaceShield STM, DroneCrypt UTM, and QuantumProof Protocol. "The Indo-Pacific region represents a critical frontier for post-quantum cybersecurity innovation as quantum computing advances threaten traditional encryption," said Matej Michalko, Founder, Chairman and CEO of Decent Cybersecurity. "Our participation demonstrates our commitment to offering Japanese defense and space agencies access to European-certified, quantum-resistant security solutions that protect critical infrastructure against emerging threats." As a holder of NATO, EU, and national security clearances at the "Secret" level, Decent Cybersecurity brings unique post-quantum security credentials to the Japan
LTIMindtree, Eurobank and Fairfax Digital Services Collaborate to Build Digital Innovation Hub in Cyprus16.5.2025 10:00:00 EEST | Press release
LTIMindtree [NSE: LTIM, BSE: 540005], a global technology consulting and digital solutions company, has announced the opening of its Digital Innovation Hub at the Research and Innovation Hub of CYENS Center of Excellence. The LTIMindtree Digital Innovation Hub will enable ideation, co-creation and implementation of Advanced Digital Solutions for Eurobank, Fairfax and other EU customers and aligns with the strategic vision of the Cyprus Government to strengthen Cyprus’ role as a regional tech and innovation hub, triggering unique cross-border opportunities for tech collaborations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250515054331/en/ Srini Rao EVP & Chief Business Officer- Europe, LTIMindtree | Mr. Nikodemos Damianou, Deputy Minister of Research and Innovation, Govt of Cyprus | Mr. Fokion Karavias, Group CEO, EUROBANK Group | Mr. Sanjay Tugnait, President & CEO, Fairfax Digital along with other esteemed client execu
ROYC Acts as the Structuring and Financial Technology Partner for Riverside for European Wealth Access Fund16.5.2025 09:30:00 EEST | Press release
ROYC, the leading provider of complete private markets operating systems, announces the structuring of a new access fund for Private Wealth launched in collaboration with The Riverside Company. The Riverside Company is a global private equity firm focused on investing in growing businesses valued at up to $400 million. Since its founding in 1988, Riverside has made more than 1,000 investments and today has over $12 billion in assets under management. The firm's international private equity and structured capital portfolios include more than 140 companies. The Riverside’s proven investment strategy of acquiring and developing high-potential European SMEs in resilient, growth-oriented sectors, including technology and software, healthcare, advanced manufacturing and consumer products. “This fund represents a unique opportunity for wealth investors to access value creation generally reserved for institutional investors,” says Karsten Langer, Managing Partner at Riverside Europe and contin
Rimini Street Announces Upcoming 2025 Investor Conference Schedule15.5.2025 23:51:00 EEST | Press release
Rimini Street, Inc. (Nasdaq: RMNI), a global provider of end-to-end enterprise software support and innovation solutions, and the leading third-party support provider for Oracle, SAP and VMware software, today announced that Michael L. Perica, chief financial officer, and Dean Pohl, vice president, treasurer and investor relations, will be presenting and meeting with investors one-on-one and in small group meetings at the following conferences: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250515374696/en/ Rimini Street Announces Upcoming 2025 Investor Conference Schedule May 28, 2025: Craig-Hallum 22nd Annual Institutional Investor Conference, Minneapolis May 29, 2025: TD Cowen 53rd Annual TMT Conference, New York City Fireside Chat: 1:15 pm Eastern, webcast link June 24-26, 2025: Roth 15th Annual London Conference, London To schedule a meeting please contact your salesperson or Rimini Street Investor Relations at IR@rimin
Incyte Announces FDA Approval of Zynyz ® (retifanlimab-dlwr) Making it the First and Only Approved First-Line Treatment for Advanced Anal Cancer Patients in the United States15.5.2025 21:30:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has approved Zynyz® (retifanlimab-dlwr), a humanized monoclonal antibody targeting programmed death receptor-1 (PD-1), in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with inoperable locally recurrent or metastatic squamous cell carcinoma of the anal canal (SCAC). In addition, the FDA granted approval for Zynyz as a single agent for the treatment of adult patients with locally recurrent or with metastatic SCAC with disease progression on or intolerance to platinum-based chemotherapy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250508024371/en/ Zynyz logo "The FDA approval of Zynyz marks a pivotal moment, bringing effective combination and monotherapy treatment options to patients with advanced anal cancer after decades of limited innovation," said Hervé Hoppenot,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom